Entries by Thomas Gabrielczyk

Dewpoint Therapeutics cuts workforce, refocuses pipeline

Dewpoint Therapeutics Inc. has announced a significant corporate restructuring. Approximately 70% of its 130 employees will be laid off, and operations will be consolidated at the company’s Boston headquarters. The company will close its two German locations in Frankfurt and Dresden and streamline its pipeline.

EU Biotech Act: Have your say!

The European Commission has launched a public consultation to support the development of the European Biotech Act, which is now being prioritised after a previous delay. The Commission plans to publish the legislative proposal by the end of 2025 and is inviting stakeholders across the biotechnology sector to provide feedback on regulatory, financial, and operational barriers.

ReiThera starts study on HIV vaccine

Italian biotech company ReiThera srl has commenced safety trials of its experimental HIV vaccine candidate, GRAdHIVNE1, in Harare, Zimbabwe. Developed in partnership with the Ragon Institute at Harvard University, this innovative HIV vaccine targets conserved regions of the viral gag, env, and pol genes to stimulate a robust cytotoxic T-cell immune response.

LIfT BioSciences Ltd receives €12m for clinical translation of IMANs

LIfT BioSciences Ltd, active in London, Galway and Houston, has been awarded a grant of €12m from the Disruptive Technologies Innovation Fund (DTIF) to support the clinical translation of its Immuno-Modulatory Alpha Neutrophils (IMANs). This funding will enable the preparation of the world’s first allogeneic therapy using synthetically programmed neutrophil granulocytes for Phase I trials.

Import tariff of 15%: significant implications for pharmaceutical firms

In the ongoing dispute over US import tariffs on European pharmaceuticals, the European Commission has acquiesced to a 15% tariff on EU pharmaceutical exports to the United States, as well as to the imposition of the same rate on EU investments exceeding US$600m in the US, without formal resistance. Industry associations have reacted with strong criticism.